The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine

M M T J Broekman; D R Wong; G J A Wanten; H M Roelofs; C J van Marrewijk; O H Klungel; A L M Verbeek; P M Hooymans; H-J Guchelaar; H Scheffer; L J J Derijks; M J H Coenen; D J de Jong

doi:10.1038/tpj.2016.87

The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine

M M T J Broekman
, D R Wong
, G J A Wanten
, H M Roelofs
, C J van Marrewijk
, O H Klungel
, A L M Verbeek
, P M Hooymans
, H-J Guchelaar
, H Scheffer
, L J J Derijks
, M J H Coenen
, D J de Jong

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The conversion of azathioprine (AZA) to mercaptopurine (MP) is mediated by glutathione transferase Mu1 (GSTM1), alpha1 (GSTA1) and alpha2 (GSTA2). We designed a case-control study with data from the TOPIC trial to explore the effects of genetic variation on steady state 6-methylmercaptopurine ribonucleotide (6-MMPR) and 6-thioguanine nucleotide (6-TGN) metabolite levels. We included 199 patients with inflammatory bowel disease (126 on AZA and 73 on MP). GSTM1-null genotype carriers on AZA had two-fold lower 6-MMPR levels than AZA users carrying one or two copies of GSTM1 (2239 (1006-4587) versus 4371 (1897-7369) pmol/8 × 10(8) RBCs; P<0.01). In patients on MP (control group) 6-MMPR levels were comparable (6195 (1551-10712) versus 6544 (1717-11600) pmol/8 × 10(8) RBCs; P=0.84). The 6-TGN levels were not affected by the GSTM1 genotype. The presence of genetic variants in GSTA1 and GSTA2 was not related to the 6-MMPR and 6-TGN levels.The Pharmacogenomics Journal advance online publication, 3 January 2017; doi:10.1038/tpj.2016.87.

Original language	English
Pages (from-to)	160–166
Number of pages	7
Journal	Pharmacogenomics Journal
Volume	18
DOIs	https://doi.org/10.1038/tpj.2016.87
Publication status	Published - 2018

Access to Document

10.1038/tpj.2016.87

tpj201687Final published version, 190 KBLicence: Taverne

Cite this

Broekman, M. M. T. J., Wong, D. R., Wanten, G. J. A., Roelofs, H. M., van Marrewijk, C. J., Klungel, O. H., Verbeek, A. L. M., Hooymans, P. M., Guchelaar, H.-J., Scheffer, H., Derijks, L. J. J., Coenen, M. J. H., & de Jong, D. J. (2018). The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine. Pharmacogenomics Journal, 18, 160–166. https://doi.org/10.1038/tpj.2016.87

@article{6fee1fbab71e47dc973f49ec90f8a384,

title = "The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine",

abstract = "The conversion of azathioprine (AZA) to mercaptopurine (MP) is mediated by glutathione transferase Mu1 (GSTM1), alpha1 (GSTA1) and alpha2 (GSTA2). We designed a case-control study with data from the TOPIC trial to explore the effects of genetic variation on steady state 6-methylmercaptopurine ribonucleotide (6-MMPR) and 6-thioguanine nucleotide (6-TGN) metabolite levels. We included 199 patients with inflammatory bowel disease (126 on AZA and 73 on MP). GSTM1-null genotype carriers on AZA had two-fold lower 6-MMPR levels than AZA users carrying one or two copies of GSTM1 (2239 (1006-4587) versus 4371 (1897-7369) pmol/8 × 10(8) RBCs; P<0.01). In patients on MP (control group) 6-MMPR levels were comparable (6195 (1551-10712) versus 6544 (1717-11600) pmol/8 × 10(8) RBCs; P=0.84). The 6-TGN levels were not affected by the GSTM1 genotype. The presence of genetic variants in GSTA1 and GSTA2 was not related to the 6-MMPR and 6-TGN levels.The Pharmacogenomics Journal advance online publication, 3 January 2017; doi:10.1038/tpj.2016.87.",

author = "Broekman, \{M M T J\} and Wong, \{D R\} and Wanten, \{G J A\} and Roelofs, \{H M\} and \{van Marrewijk\}, \{C J\} and Klungel, \{O H\} and Verbeek, \{A L M\} and Hooymans, \{P M\} and H-J Guchelaar and H Scheffer and Derijks, \{L J J\} and Coenen, \{M J H\} and \{de Jong\}, \{D J\}",

year = "2018",

doi = "10.1038/tpj.2016.87",

language = "English",

volume = "18",

pages = "160–166",

journal = "Pharmacogenomics Journal",

issn = "1470-269X",

publisher = "Springer Nature",

}

Broekman, MMTJ, Wong, DR, Wanten, GJA, Roelofs, HM, van Marrewijk, CJ, Klungel, OH, Verbeek, ALM, Hooymans, PM, Guchelaar, H-J, Scheffer, H, Derijks, LJJ, Coenen, MJH & de Jong, DJ 2018, 'The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine', Pharmacogenomics Journal, vol. 18, pp. 160–166. https://doi.org/10.1038/tpj.2016.87

TY - JOUR

T1 - The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine

AU - Broekman, M M T J

AU - Wong, D R

AU - Wanten, G J A

AU - Roelofs, H M

AU - van Marrewijk, C J

AU - Klungel, O H

AU - Verbeek, A L M

AU - Hooymans, P M

AU - Guchelaar, H-J

AU - Scheffer, H

AU - Derijks, L J J

AU - Coenen, M J H

AU - de Jong, D J

PY - 2018

Y1 - 2018

N2 - The conversion of azathioprine (AZA) to mercaptopurine (MP) is mediated by glutathione transferase Mu1 (GSTM1), alpha1 (GSTA1) and alpha2 (GSTA2). We designed a case-control study with data from the TOPIC trial to explore the effects of genetic variation on steady state 6-methylmercaptopurine ribonucleotide (6-MMPR) and 6-thioguanine nucleotide (6-TGN) metabolite levels. We included 199 patients with inflammatory bowel disease (126 on AZA and 73 on MP). GSTM1-null genotype carriers on AZA had two-fold lower 6-MMPR levels than AZA users carrying one or two copies of GSTM1 (2239 (1006-4587) versus 4371 (1897-7369) pmol/8 × 10(8) RBCs; P<0.01). In patients on MP (control group) 6-MMPR levels were comparable (6195 (1551-10712) versus 6544 (1717-11600) pmol/8 × 10(8) RBCs; P=0.84). The 6-TGN levels were not affected by the GSTM1 genotype. The presence of genetic variants in GSTA1 and GSTA2 was not related to the 6-MMPR and 6-TGN levels.The Pharmacogenomics Journal advance online publication, 3 January 2017; doi:10.1038/tpj.2016.87.

AB - The conversion of azathioprine (AZA) to mercaptopurine (MP) is mediated by glutathione transferase Mu1 (GSTM1), alpha1 (GSTA1) and alpha2 (GSTA2). We designed a case-control study with data from the TOPIC trial to explore the effects of genetic variation on steady state 6-methylmercaptopurine ribonucleotide (6-MMPR) and 6-thioguanine nucleotide (6-TGN) metabolite levels. We included 199 patients with inflammatory bowel disease (126 on AZA and 73 on MP). GSTM1-null genotype carriers on AZA had two-fold lower 6-MMPR levels than AZA users carrying one or two copies of GSTM1 (2239 (1006-4587) versus 4371 (1897-7369) pmol/8 × 10(8) RBCs; P<0.01). In patients on MP (control group) 6-MMPR levels were comparable (6195 (1551-10712) versus 6544 (1717-11600) pmol/8 × 10(8) RBCs; P=0.84). The 6-TGN levels were not affected by the GSTM1 genotype. The presence of genetic variants in GSTA1 and GSTA2 was not related to the 6-MMPR and 6-TGN levels.The Pharmacogenomics Journal advance online publication, 3 January 2017; doi:10.1038/tpj.2016.87.

U2 - 10.1038/tpj.2016.87

DO - 10.1038/tpj.2016.87

M3 - Article

C2 - 28045129

SN - 1470-269X

VL - 18

SP - 160

EP - 166

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

ER -

The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine

Abstract

Access to Document

Fingerprint

Cite this